Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Hansa Biopharma: 12‑month data from kidney transplant study to be presented at ATC on June 22

Hansa Biopharma announced that the 12‑month results of the US phase‑3 ConfIdeS study of imlifidase have been accepted for presentation at the American Transplant Congress in Boston on June 22, 2026. The presentation will cover the primary endpoint eGFR, key secondary endpoints and safety data and will be given by Dr. Robert Montgomery. Separately, the FDA accepted the regulatory filing for imlifidase in February 2026 and set a decision date of December 19, 2026. » Mere på de.investing.com
Hansa Biopharma: revenue in Q3 2025 falls 37%, shares slump

Hansa Biopharma reported a 37% drop in revenue for Q3 2025 to SEK 31m, leading to a roughly 12% fall in its share price. Idefirix sales fell 24%, operating loss widened to SEK 147.6m and gross margin climbed to 60%. Management points to positive phase‑3 data for Imlifidase and is preparing a potential FDA filing with possible market entry in 2026, but continues to see regulatory and market risks. » Mere på de.investing.com
Hansa Investment approves merger with Ocean Wilsons after shareholder consent

Hansa Investment shareholders voted at the general meeting with an overwhelming majority (each over 97%) in favor of all resolutions required for the planned share-swap merger with Ocean Wilsons. The resolutions include a capital increase, a new investment policy, higher total remuneration for directors and buyback programmes. The court hearing to approve the scheme begins on 22 September 2025; subject to court approval, new Hansa shares are to be issued shortly thereafter and admitted to trading on the London Stock Exchange. The transaction remains subject to court approval and other conditions and has a long-stop date of 31 December 2025. » Mere på de.investing.com
Hansa Investment Company Limited merges with Ocean Wilsons to form £900 million investment company

Hansa Investment Company Limited and Ocean Wilsons Holdings Limited have agreed to a share exchange that will create an investment company with net assets exceeding £900 million. The new company will manage a diversified global portfolio, achieve cost savings through a new fee structure, and prioritize share buybacks over dividends. The transaction is subject to shareholder approval and is expected to be completed in September 2025. » Mere på de.investing.com
Hansa Biopharma reports strong revenue growth and pipeline progress despite operating losses

Hansa Biopharma increased product revenue by 76% in the second quarter of 2025 and achieved significant progress in its clinical pipeline, but missed overall revenue and earnings forecasts. The company stabilized its financial position through a capital increase and restructuring measures, yet continues to face operating losses and market uncertainties. Key clinical trial results are expected in the second half of the year, while acceptance of its main product, IDEFIRIX, continues to grow in Europe. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Hansa Biopharma en omsætning på 4,34 mio. € og et nettoresultat på -23,51 mio. €

(EUR)	juni 2026	YoY
Omsætning	4,34 mio.	1,55 %
Bruttofortjeneste	2,33 mio.	16,04 %
Nettoresultat	-23,51 mio.	46,44 %
EBITDA	-17,12 mio.	22,89 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	369,77 mio. €
Antal aktier	88,53 mio.
Højeste/laveste i 52 uger	4,45 € - 2,12 €
Udbytte	Nej
Beta	1,66
P/E (PE Ratio)	-5,89
PEG (PEG Ratio)	2,26
K/I (PB Ratio)	-9,05
P/S (PS Ratio)	21,63

Virksomhedsprofil

Hansa Biopharma AB (publ), et biofarmaceutisk selskab, udvikler immunmodulerende behandlinger til muliggørelse af transplantationer og sjældne immunglobulin G (IgG)-medierede autoimmune tilstande, genterapi og kræft ved hjælp af sin patenterede enzymteknologiplatform. Selskabets førende lægemiddelkandidat er Imlifidase, en antistofspaltende enzymbehandling, der er i fase 3 klinisk forsøg til brug for sensibiliserede nyretransplantationspatienter samt for anti-GBM-antistofsygdom; og i fase 2 klinisk forsøg for antistofmedieret afstødning af nyretransplantater og Guillain-Barré syndrom. Selskabet udvikler også Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) til behandling af autoimmune sygdomme, transplantation og onkologi; samt Enzyme based antibody Enhancement (EnzE), som er kræftimmunterapi. Selskabet har en præklinisk forskningssamarbejdsaftale med argenx BV for at evaluere det terapeutiske potentiale ved at kombinere de to selskabers IgG-modulerende teknologier. Hansa Biopharma AB (publ) blev stiftet i 2007 og har hovedsæde i Lund, Sverige.